Top ▲

Myelodysplastic syndrome

Disease ID:1201
Name:Myelodysplastic syndrome
Associated with:0 target
2 immuno-relevant ligands
A bone marrow cancer characterized by insufficient production of white blood cells, red blood cells and platelets.
Database Links
Disease Ontology: DOID:0050908
OMIM: 614286


No target related data available for Myelodysplastic syndrome


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: Approved drug for myelodysplastic syndrome.
Clinical Use: Antineoplastic agent used in the treatment of myelodysplastic syndrome.
(an HDAC inhibitor, which has an epigenetic priming effect [1]) is being evaluated in a Phase 2 clinical trial alongside azacitidine prior to check-point immunotherapy with in patients with recurrent metastatic non-small cell lung cancer- see NCT01928576. Onureg® was approved by the EMA in 2021, for the treatment of AML. | View clinical data
Bioactivity Comments: We have been unable to find publicly available affinity data for this drug at its proposed molecular target(s) to substantiate its MMOA, and have therefore not tagged a primary drug target. | View biological activity
Immuno Disease Comments: Phase 2 candidate for myelodysplastic syndrome, but has not progressed further.
Clinical Use: Talmapimod has been assessed in several completed Phase 2 clinical trials for myelodysplastic syndromes and active rheumatoid arthritis. Click here for's full list of completed talmapimod (SCIO-469) trials. There are no active trials registered with (Nov 2014). | View clinical data


Show »

1. Dear AE. (2016) Epigenetic Modulators and the New Immunotherapies. N Engl J Med, 374 (7): 684-6. [PMID:26886527]